Compare GTE & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | SPRO |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.1M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | GTE | SPRO |
|---|---|---|
| Price | $4.71 | $2.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 507.5K | 433.6K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $611,444,000.00 | $40,549,000.00 |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $1.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.09 | $0.51 |
| 52 Week High | $8.19 | $3.22 |
| Indicator | GTE | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 45.55 |
| Support Level | $4.47 | $2.18 |
| Resistance Level | $4.81 | $2.33 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 80.00 | 20.51 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.